Cantargia presents new robust data at ASCO 2022 confirming promising effects of nadunolimab in treatment of pancreatic c
(NASDAQ Stockholm: CANTA) today reported extended interim results in first-line pancreatic cancer (PDAC)...
Prnewswire Cantargia Eric Van Cutsem Precision Promise Accessory Protein Poster Discussion Session Gastrointestinal Cancer
Source: europapress.es